Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma.

Scientific reports - 11 Dec 2019

Jain Ankit P, Patel Krishna, Pinto Sneha, Radhakrishnan Aneesha, Nanjappa Vishalakshi, Kumar Manish, Raja Remya, Patil Arun H, Kumari Anjali, Manoharan Malini, Karunakaran Coral, Murugan Saktivel, Keshava Prasad T S, Chang Xiaofei, Mathur Premendu Prakash, Kumar Prashant, Gupta Ravi, Gupta Rohit, Khanna-Gupta Arati, Sidransky David, Chatterjee Aditi, Gowda Harsha

Abstract excerpt

Epidermal growth factor receptor (EGFR) targeted therapies have shown limited efficacy in head and neck squamous cell carcinoma (HNSCC) patients despite its overexpression. Identifying molecular mechanisms associated with acquired resistance to EGFR-TKIs such as erlotinib remains an unmet need and a therapeutic challenge. In this study, we employed an integrated multi-omics approach to delineate mechanisms...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Datasets as Topic
Share to Drug Delivery Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epithelial-Mesenchymal Transition

Share to Erlotinib Hydrochloride

Share to MAP Kinase Kinase 1

Share to Metabolic Networks and Pathways

Share to Proteomics

Share to Squamous Cell Carcinoma of Head and Neck

Source

Open in PubMed Open full text

Identifiers

PMID: 31827134
DOI: 10.1038/s41598-019-55208-5
PMCID: PMC6906491

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma.PMID 31827134Read ↗

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.Semantic proximity Read ↗

Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell CarcinomasSemantic proximity Read ↗

Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma (Review)Semantic proximity Read ↗

New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors.Semantic proximity Read ↗

Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.Semantic proximity Read ↗

Global proteome and phosphoproteome alterations in third generation EGFR TKI resistance reveal drug targets to circumvent resistanceSemantic proximity Read ↗

Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent ResistanceSemantic proximity Read ↗

Dissecting signaling regulators driving AXL-mediated bypass resistance and associated phenotypes by phosphosite perturbationsSemantic proximity Read ↗

Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell linesSemantic proximity Read ↗

Whole exome sequencing uncovers HRAS mutations as potential mediators of resistance to metronomic chemotherapy.Semantic proximity Read ↗

The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

EGFR Mutations in Head and Neck Squamous Cell Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.